Amarin Co. plc (NASDAQ:AMRN) gapped up before the market opened on Tuesday . The stock had previously closed at $17.11, but opened at $17.62. Amarin shares last traded at $18.19, with a volume of 6,287,447 shares trading hands.
A number of research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Amarin from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. began coverage on shares of Amarin in a research report on Monday, January 6th. They set a “neutral” rating and a $22.00 target price for the company. Leerink Swann reissued a “buy” rating and set a $29.00 target price on shares of Amarin in a research report on Friday, December 13th. Cantor Fitzgerald reissued a “buy” rating and set a $35.00 target price on shares of Amarin in a research report on Thursday, January 2nd. Finally, Aegis began coverage on shares of Amarin in a research report on Thursday, October 31st. They set a “buy” rating and a $23.00 target price for the company. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $27.38.
The stock’s 50-day moving average is $19.36 and its 200-day moving average is $18.22. The stock has a market cap of $6.29 billion, a price-to-earnings ratio of -90.95 and a beta of 1.08. The company has a current ratio of 3.69, a quick ratio of 3.45 and a debt-to-equity ratio of 0.02.
About Amarin (NASDAQ:AMRN)
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Recommended Story: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.